TNFRSF17 and plasma cell neoplasm: In a study involving one patient with plasma cell leukemia, a highly aggressive plasma cell neoplasm, who received anti-BCMA CAR-T therapy, analysis of scRNA-seq validated the capability of CAR-T cells to recruit endogenous T cells in vivo, potentially exerting reciprocal effects on CAR-T cells and modulating the microenvironment (32).